Two-Stage Hepatectomy for Irresectable Hepatic Tumor

Two-Stage Hepatectomy (TSH) is an advanced surgical strategy designed to treat patients with irresectable hepatic tumors, particularly those with colorectal liver metastases (CRLM), which were previously deemed inoperable due to the extent or distribution of the disease. Below is a detailed explanation of the process, feasibility, risks, outcomes, and its potential as a curative approach:

### **Overview of Two-Stage Hepatectomy:**

TSH is a stepwise surgical approach used for patients with multinodular or bilobar liver metastases. Many of these patients cannot undergo a single-stage resection due to insufficient remaining liver volume, which is critical for postoperative liver function. The two-stage procedure allows for safe and complete resection of tumors while ensuring that the liver has sufficient time to regenerate between surgeries.

### **Rationale for TSH:**

• **Challenge:** Patients with bilobar or extensive liver metastases often have insufficient functional liver reserve to tolerate a single, extensive resection.
• **Solution:** TSH involves two surgeries. The first surgery removes the maximum number of tumors while preserving liver parenchyma to allow regeneration. The second surgery is performed after the liver has sufficiently regenerated to remove the remaining tumors.

### **Patient Selection and Study Population:**

• Out of 634 patients with colorectal liver metastases (CRLM) treated between 1992 and 1999, 398 had irresectable disease.
• Only 16 patients (4%) became eligible for TSH after receiving systemic chemotherapy, and 13 of these patients successfully completed both stages.
• Key eligibility factors included:
• Disease control with systemic chemotherapy.
• Absence of extrahepatic metastases (except for select cases of resectable pulmonary metastases).

### **Chemotherapy as a Bridge to Surgery:**

• All patients underwent systemic chemotherapy before surgery to stabilize or shrink tumors, making resection feasible. The regimens primarily included 5-fluorouracil (5-FU) combined with oxaliplatin or irinotecan.
• Chemotherapy continued during the interval between the two surgeries to prevent tumor progression.

### **Surgical Strategy:**

1. **First Stage:**

• The goal was to perform tumor debulking by resecting the maximum number of tumors while preserving enough liver parenchyma for regeneration.
• Techniques included partial hepatectomy or lobar clearance guided by intraoperative ultrasound.

2. **Second Stage:**

• After a median interval of 4 months (range: 2–14 months), the second surgery was performed.
• This stage typically involved a more extensive resection (e.g., removal of >3 liver segments) to eliminate the remaining tumors.
• Portal vein embolization (PVE) was used in 6 patients to induce hypertrophy of the future liver remnant (FLR) and ensure safe resection in the second stage.
• Cryosurgery was used in one patient for non-resectable lesions.

### **Feasibility and Success Rates:**

• The complete two-stage procedure was feasible in 81% (13 out of 16) of selected patients.
• Three patients (19%) were unable to proceed to the second stage due to disease progression during the interval period.

### **Morbidity and Mortality:**

• **Morbidity:**
• Postoperative complications occurred in 31% of patients following the first stage and 45% after the second stage.
• Common complications included transient ascitic leaks, perihepatic collections, and one case of bowel obstruction.
• **Mortality:**
• No deaths were reported after the first stage.
• Two patients (15%) died after the second stage due to postoperative liver failure, highlighting the increased complexity and physiological burden of the second surgery.

### **Survival Outcomes:**

• The median overall survival was 44 months from diagnosis and 31 months from the second hepatectomy.
• The 3-year overall survival rate following TSH was 35%.
• Four patients (31%) achieved long-term disease-free survival, remaining disease-free at 7, 22, 36, and 54 months post-procedure.
• Patients who completed both stages of TSH lived significantly longer than those who could not proceed to the second stage, confirming the potential curative benefit of this approach.

### **Tumor Recurrence:**

• Tumor recurrence occurred in 7 of 13 patients (54%), with the majority being hepatic recurrences within an average of 8 months after the second surgery.
• Repeat hepatectomy was feasible in select cases, and some patients achieved prolonged survival or disease-free status despite recurrence.

### **Key Predictive Factors for Success:**

• Strict patient selection is critical for TSH success.
• The following factors were identified as important predictors of positive outcomes:
• Effective disease control with chemotherapy.
• Absence of extrahepatic metastases (except resectable pulmonary metastases).
• Adequate liver hypertrophy and function between stages.

### **Clinical Implications:**

• TSH significantly increased the resection rate among initially irresectable patients, from 37% to 54% in the study population.
• The approach offers a potentially curative option for patients who would otherwise be limited to palliative care with systemic chemotherapy.
• Integration of systemic chemotherapy and techniques such as portal vein embolization enhances the safety and success of the procedure.

### **Conclusion:**

Two-Stage Hepatectomy, when combined with systemic chemotherapy and advanced surgical techniques, represents a transformative approach for select patients with irresectable colorectal liver metastases. Despite the risks associated with the procedure, the potential for long-term survival and even cure makes it a viable option for appropriately selected patients.